New Delhi, 13 March (IANS). The price of a normal drug of diabetes called ampagliflose has been cut. Now its price is left about tenth as compared to before. This change came when many companies launched the generic versions of this drug in the market.
Empagliflose was developed by German pharmaceutical company Bohringer Ingelheim (BI) and is sold as Jardians. It is a mouth-receiving drug, which helps in controlling blood sugar (blood sugar) of type-2 diabetes patients.
Earlier, a pill of this medicine was available for about 60 rupees, but now it has been priced at only Rs 5.5 per pill. This cut was possible when companies like Mankind, Alchem and Glenmark launched its generic versions in the market.
Mankind Pharma has said that its ampgliflogen drug will now be available at a rate of Rs 5.49 per tablet for 10 mg dose and Rs 9.90 per tablet for 25 mg. The company’s vice -president and managing director Rajiv Juneja said, “We are making sure that the cost of the drug should no longer be an obstacle in treatment.”
The alchem company has launched this drug under the name “Emponom”, which has been priced by about 80 percent less than the original medicine. The company said that a special safety band has been installed on this drug packet to protect against fake medicines. Also, to make patients aware, the pack has information related to diabetes management in Hindi and English language with pictures. In addition, a QR code has also been given, from which additional information related to diabetes, heart disease and kidney disease can be obtained in 11 languages.
Mumbai -based Glenmark Pharmaceuticals have also launched a generic version of Empagliflogen as “Glampa”. In addition, it has also launched drugs with its mixed dosage called “Glampa-L” (Empaglyzin + Linaglipin) and “Glampa-M” (Empaglogen + Metformin).
Alok Malik, president of Glenmark Pharma, said, “This new drug of Glampa category will give affordable and effective treatment to patients suffering from type-2 diabetes, which will also improve patients affected by heart disease.”
India is called the capital of diabetes, where in 2023, according to a study by the Indian Council of Medical Research (Diabetes), more than 100 million people were found to be suffering from the disease.
As such, reducing the price of diabetes drugs can be an important step towards reducing the increasing burden of this disease.
-IANS
AS/
